CHINARES PHARMA (03320) · Company profile · Eqvero

CHINARES PHARMA

03320HKEX

Unit: CNY	FY2025	FY2024	FY2023
Revenue	269.57 bn CNY	257.67 bn CNY	244.7 bn CNY
Cost of revenue	220.98 bn CNY	213.63 bn CNY	203.2 bn CNY
Research and development expense	2.83 bn CNY	2.33 bn CNY	2.48 bn CNY
Selling, general and administrative expense	29.18 bn CNY	26.56 bn CNY	25.25 bn CNY
Operating profit after depreciation	12.65 bn CNY	11.98 bn CNY	11.04 bn CNY
Operating profit before depreciation	16.73 bn CNY	15.34 bn CNY	14.21 bn CNY
EBIT	12.65 bn CNY	11.98 bn CNY	11.04 bn CNY
EBITDA	16.73 bn CNY	15.34 bn CNY	14.21 bn CNY
Interest expense	2.01 bn CNY	2.26 bn CNY	2.37 bn CNY
Profit before tax	11.8 bn CNY	10.93 bn CNY	9.88 bn CNY
Income tax expense	2.14 bn CNY	2.53 bn CNY	2.11 bn CNY
Income before extraordinary items	4.05 bn CNY	3.35 bn CNY	3.85 bn CNY
Common dividends	1.22 bn CNY	848.45 m CNY	968 m CNY
Total dividends	1.22 bn CNY	848.45 m CNY	968 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.